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To provide a quantitative description of the treatments applied to malignant colorectal cancer across 
Europe, we analysed all cases (11333) of colorectal cancer registered in 1987 by 15 Cancer Registries in 
eight European countries. In a third of cancer registries, therapy was known for all cases, in the others 
l-15% of registrations lacked treatment information. Eighty per cent of all patients received surgical 
resection, ranging from 58% (Estonia) to 92% (Tarn). The proportion of resections decreased with 
advancing age (85-73% for colon cancer; 85-70% for rectal cancer for <65 years to >74 years, 
respectively). Only 4% of colon cancer patients received adjuvant or palliative chemotherapy, range l- 
12%. Sixteen per cent of rectal cancer patients received radiotherapy with great inter-registry varia- 
bility (l-43%). Since the proportion of surgically resected patients correlated positively with the 5-year 
relative survival probability reported by the recently published EUROCARE study, this may be part of 
the explanation for the major differences in survival for these cancers among different European 
populations. The most likely determinant of this correlation is stage at diagnosis, but, quality of, and 
access to surgery, as well as access to endoscopy, may differ among countries and registry areas, and 
these may also contribute to inter-country survival differences. Copyright 0 1996 Elsevier Science Ltd 
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INTRODUCTION 
BASED ON combined data collected by 30 population-based 
cancer registries for cases diagnosed during 1978-1985 and 
analysed by EUROCARE, the 5year relative survival for 
colorectal cancer patients in Europe was approximately 40% 
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[ 11. However, there were conspicuous geographical variations 
in this statistic: from over 45% in cancer registries from 
Switzerland, South-east Netherlands and Finland to less than 
35% in cancer registries from England and Poland [ 11. 
The aim of the present study was to provide a quantitative 
description of the types of treatment applied to colorectal 
cancer in European countries, based on information routinely 
collected by cancer registries during 1987. This may help 
us to understand why there are marked between-country 
differences in survival from these cancers across Europe. The 
study was carried out within the EUROCARE network of 
cancer registries, under the auspices of an EC Concerted 
Action programme, responsible for evaluating and standardis- 
ing population-based cancer survival data and reporting on 
cancer patient survival and care practices in Europe. 
PATIENTS AND METHODS 
The study analysed all the colorectal (ICD-9 153,154) [2] 
cancers occurring in 1987 in 15 European populations, for 
whom relatively complete data on treatment were available, 
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covered by cancer registries in eight countries. Only malignant 
invasive turnours, as defined by ICD-0 behaviour code 3 or 
higher [3] were considered; in situ, uncertain and borderline 
tumours were excluded, as were carcinoids and non-epithelial 
tumours. Both microscopically verified and non-verified cases 
were included, but cases known to registries by death certifi- 
cate only (DCO) or discovered incidentally at autopsy, were 
excluded. 
Table 1 shows a breakdown of the total 11 333 colorectal 
cancer cases according to participating cancer registry and 
country. The registries of Finland and Estonia cover the entire 
populations of those countries. France, The Netherlands, 
Switzerland and the U.K. are represented by two or more 
registries. Italy and Poland are represented by single registries 
covering small areas. Most of the cases were from registries in 
Northern Europe and almost 50% were from the two U.K. 
registries. Table 1 also provides information on the distri- 
bution by sex, age and cancer site according to registry. The 
proportion of males ranged from 44% (Finland) to 59% (Cote 
d’Or). 43% of cases were over 74 years of age, varying between 
28% (Estonia and Cracow) and 46% (Geneva and Basel). 
The number of colon cancer cases was usually slightly higher 
than that of rectal cancer. The proportion of cases confirmed 
either histologically or cytologically (“microscopically 
verified”) generally ranged between 80% (Mersey) and 99% 
(Base1 and Eindhoven), but in Cracow only 45% of cases were 
“microscopically” confirmed. 
The major sources of information for most cancer registries 
Table 1. Colorectal cancer cases by registry, sex, age, site and 
microscopic verification (Mv 
Registry 
No. of Males 174years Colon MV% 
cases % of age % 
(%) % 
Estonia 415 (4) 45 28 54 87 
Finland* 1422 (13) 44 38 58 95 
France 
CBte d’Or 244 (2) 
Calvados 249 (2) 
Doubs 175 (2) 
Tarn 200 (2) 
Amiens 249 (2) 
Italy 
Varese 421 (4) 
The Netherlands 
Eindhoven 389 (3) 
Rotterdam 732 (6) 
Poland 
Cracow 200 (2) 
Switzerland 
Base1 485 (4) 
Geneva 184 (2) 
U.K. 
Mersey 1163 (10) 
Thames* 4805 (42) 
Total 11333 (100) 
59 43 69 98 
54 41 57 98 
53 31 56 98 
53 45 59 97 
53 37 59 95 
49 39 62 90 
52 36 68 99 
48 42 66 97 
45 28 51 45 
54 46 63 99 
48 46 71 95 
49 40 60 80 
48 44 62 87 
49 43 61 90 
*No re-check of therapy data. 
are medical records and pathology files and sometimes death 
certificates, to collect a minima1 set of information for routine 
cancer incidence studies. 
Cancer registries were asked to provide information on 
whether patients underwent surgical resection and/or radio- 
therapy, chemotherapy or other treatment. If surgical resec- 
tion, radiotherapy, chemotherapy or other treatment was men- 
tioned in the registry file, it was entered as such; if none were 
mentioned, the item was entered as “therapy not known”. 
Detailed information on type of surgery, or radiotherapeutic 
or chemotherapeutic regimen adopted was not requested. 
However, to provide as complete a picture as possible on 
therapy, the participating registries were asked to re-check 
the clinical records of patients for whom no information on 
treatment had been recorded. Two large registries (Finland 
and Thames) did not perform this check. 
Surgical resection was defined as any surgical intervention 
which removed the tumour, whether with radical or palliative 
intent. When only by-pass surgery was performed, it was 
classified as “other treatment”, although the Finnish cancer 
registry could not separate by-pass surgery from resection as 
defined above. 
Because the age-distributions of patients differed between 
registries, the proportions of patients given particular types of 
treatment were age-adjusted using the direct method, i.e. the 
proportion of cases treated in each IO-year age group (<35, 
35-44, 45-54, 55-64, 65-74, 75+) for each registry was 
applied to the age distribution of the total series of cases. The 
age-stratified homogeneity test was used for testing treatment 
differences between cancer registries or between countries [4]. 
RESULTS 
Table 2 shows the (age-adjusted) percentages of colorectal 
cancer patients who received surgical resection either alone or 
in association with chemotherapy or radiotherapy, and the 
percentages of patients given “other treatments” 
(symptomatic or palliative, including chemotherapy, radio- 
therapy and by-pass surgery). In 8% of cases, there was no 
information on therapy. Overall, 80% of patients received 
surgical resection, varying from 58% (Estonia) to 92% (Tarn) 
by registry, with Estonia, Amiens, Cracow and Mersey cancer 
registries less than 70%. 
Tables 3 and 4 show, for colon and rectum, respectively, 
the percentages of patients treated surgically, according to 
registry and age. The proportion treated surgically decreased 
with advancing age: from 85 to 73% for colon cancer, and 
from 85 to 70% for rectal cancer. This trend was evident for 
both cancer sites in most cancer registries. The proportion of 
treated patients aged over 74 ranged from 43% (Estonia) to 
94% (Doubs) for colon cancer, and from 33% (Amiens) to 
82% (Tarn, Rotterdam and Basel) for rectal cancer. Fairly 
large differences between registries, with respect to pro- 
portions receiving surgery, were also evident in the younger 
and in the middle age-group. 
In addition to between-country variability, there was con- 
siderable variability within countries, which was particularly 
significant in France, Switzerland and the U.K. for both 
colon and rectal cancers (all ages, P < 0.005). No treatment 
differences in relation to sex were observed (not reported 
in Table). 
Table 5 shows the age-standardised percentages of colon 
cancer patients who received chemotherapy, and rectal cancer 
patients given radiotherapy. Overall, only 4% of patients with 
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Table 2. Colorectal cancer cases according to regimy and therapy. Table 3. Surgical resection in colon cancer patients according to 
Age-standardised percentages registry and age. Age-standardised percentages 
Therapy Age-groups 
Registry 
Surgical Other Not 
resection* treatmentst known 
% % (%I 
Registry 
<65 65-74 >74 All 
%* % % “/t 
Estonia 
Finland* 
France 
CBte d’Or 
Calvados 
Doubs 
Tarn 
Amiens 
Italy 
Varese 
The Netherlands 
Eindhoven 
Rotterdam 
Poland 
Cracow 
Switzerland 
Base1 
Geneva 
U.K. 
Mersey 
Thames$ 
Total 
58 39 2 
82 13 6 
86 14 - 
81 16 3 
89 11 - 
92 4 4 
67 29 4 
72 27 1 
89 10 - 
87 12 - 
60 25 15 
89 10 1 
79 21 - 
66 27 7 
83 3 14 
80 12 8 
Estonia 
Finland* 
France 
CBte d’Or 
Calvados 
Doubs 
Tam 
Amiens 
Italy 
Varese 
The Netherlands 
Eindhoven 
Rotterdam 
Poland 
Cracow 
Switzerland 
Base1 
Geneva 
U.K. 
Mersey 
Thames* 
74 68 43 59 
91 87 70 81 
92 91 80 87% 
92 96 78 87 
100 93 89 93 
92 96 94 94 
100 93 91 94 
80 79 54 69 
84 87 56 73 
90 92 85 8911 
88 94 87 90 
92 90 84 88 
52 55 65 59 
97 93 78 88§ 
97 96 82 90 
96 88 67 81 
84 86 73 80§ 
73 75 56 66 
87 89 77 83 
Total 85 86 73 8011 
*Surgery with or without radiotherapy or chemotherapy.tIncludes 
radiotherapy or chemotherapy when given alone, as well as other 
symptomatic treatments. *No re-check of therapy data. 
colon cancer received chemotherapy: varying from about 1% 
in CBte d’Or, The Netherlands and Mersey to 12% in Estonia 
and Doubs. Almost all colon cancer cases treated with chemo- 
therapy also received surgical resection. Sixteen per cent of 
rectal cancer patients received radiotherapy, with great varia- 
bility between registries (143%). Overall, radiotherapy for 
rectal cancer was associated with surgical resection in 75% 
of cases. The proportion of colon cancer patients receiving 
chemotherapy decreased with advancing age (from 11% under 
65 years, to 1% over 75 years) as did the proportion of rectal 
cancer patients receiving radiotherapy (from 20% under 65 
years to 10% over 75 years). 
*Age-standardised percentages (four age categories: <35, 3544, 45- 
54, 55-64). tAge-standardised percentages (six age categories: <35, 
35-44, 45-54, 55-64, 65-74 and >74). *No re-check of therapy 
data. §Test for homogeneity within country: P< 0.005. /ITest for 
homogeneity within country: P=O.396. ITest for homogeneity 
between countries: P < 0.001, between registries: P < 0.001. 
of cases that received a by-pass operation only. Note that, 
although this registry was unable to re-check its “therapy not 
known” cases (6% of total), 76% of these were histologically 
verified, suggesting that some of them had been resected. In 
contrast, the Cracow registry had a low proportion of surgical 
resections (60%) and the highest proportion of “therapy not 
known” (15%). Before verification, these figures were 54% 
and 30%, respectively, suggesting that the remaining 15% of 
unknown therapy patients included very few who were 
resected. 
DISCUSSION 
This study reveals that the proportion of colorectal cancer 
patients who received surgical resection varied widely within 
Europe in 1987. Surgical resection was performed in over 
80% of colon and rectal cancer cases in four of the five French 
areas, The Netherlands, one of the two Swiss areas, Thames 
(U.K.) and Finland. By contrast, Estonia, Cracow, Mersey 
(U.K.) and Amiens reported that less than 70% of patients 
underwent surgical treatment, while Varese and Geneva had 
intermediate figures. 
In the Finnish cancer registry, with a high proportion of 
surgical resections, this category may include a small number 
Cases notified to the registries by death certificate only were 
excluded from this analysis. These are patients who were not 
admitted to hospital, and for whom only palliative or no 
therapy was given; generally they remain at home for the 
terminal phase of their illness. Some cancer registries with a 
low proportion of DCOs actively sought clinical information 
on cases initially identified through death certificates, leading 
to the inclusion of unfavourable cases. The proportion of 
DC0 cases was highest in Poland and Thames (U.K.) and 
lowest in Switzerland and Varese, so it is unlikely that the 
proportion of DC0 cases substantially affected the proportion 
of treated patients. Furthermore, a recent study has provided 
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Table 4. Surgical resection in rectal cancer patients according to 
registry and age. Age-standardised percentages 
Age-groups 
Registry 
<65 65-74 >74 All 
% * % % %t 
Estonia 
Finlandt 
France 
C&e d’Or 
Calvados 
Doubs 
Tarn 
Amiens 
Italy 
Varese 
The Netherlands 
Eindhoven 
Rotterdam 
Poland 
Cracow 
Switzerland 
Base1 
Geneva 
U.K. 
Mersey 
Thamesz 
75 67 35 57 
91 85 76 84 
87 88 59 77s 
86 94 73 84 
81 76 44 66 
86 100 68 83 
94 89 82 88 
85 86 33 66 
76 82 53 69 
90 89 80 8611 
94 97 76 88 
90 85 82 86 
72 60 58 63 
90 86 76 869 
92 88 82 87 
83 79 58 72 
85 83 72 8@ 
78 70 54 66 
88 86 76 83 
Total 85 82 70 78R 
*Age-srandardised percentages (four age categories: <35, 35-44, 45- 
54, 55-64). i-Age-standardised percentages (six age categories: <35, 
35-44, 45-54, 55-64, 65-74 and >74). fNo re-check of therapy 
data. §Test for homogeneity within country: Pi 0.005. IlTest for 
homogeneity within country: P= 0.19 1. fTest for homogeneity 
between countries: P < 0.001, between registries: Pi 0.001. 
evidence that the proportion of DC0 cases does not affect 
colon cancer survival figures [5]. 
In most registries, the frequency of surgical treatment 
decreased with advancing age, while the proportion of patients 
treated symptomatically, or for whom no information on 
therapy was recorded, increased with age. Stage is not neces- 
sarily more unfavourable for elderly patients with colorectal 
cancer [6], but concomitant disease may more frequently 
contraindicate surgery. 
This study gives an indication of the application of chemo- 
therapy and radiotherapy for colon and rectal cancers, respect- 
ively. However, registries often could not distinguish between 
the adjuvant or palliative intent of these therapies. In 1987, 
radiotherapy was known to be efficacious in rectal cancer [7], 
mainly to decrease the risk of local recurrence in Dukes’ B 
and C, which constitute up to 60% of cases. The large 
variation between registries in the application of radiotherapy 
for rectal cancer (range l-43%) certainly reflects different 
clinical attitudes, but may also be related to the availability of 
radiotherapy facilities. Studies showing that adjuvanr chemo- 
therapy could be efficacious in colon cancer appeared only 
after 1987 [8]. Chemotherapy was, in fact, only given to l- 
12% of patients. 
Table 5. Chemotherapy (CT) in colon and radiotherapy (RT) 
in rectal cancer patienrs according to registry. Age-standardised 
percentages (in parentheses CT or RT associared with resection) 
Registry 
Colon Rectum 
CT RT 
% % % % 
Estonia 
Finland* 
France 
CBte d’Or 
Calvados 
Doubs 
Tarn 
Amiens 
Italy 
Varese 
The Netherlands 
Eindhoven 
Rotterdam 
Poland 
Cracow 
Switzerland 
Base1 
Geneva 
U.K. 
Mersey 
Thames* 
Total 4/l 
12 
6 
7t 
9 
I2 
9 
8 
lf 
1 
2 
35 
3 
5 
4t 
5 
(9) 15 
(5) 14 
(6) 28t 
(I) 26 
(9) 43 
(12) 37 
(8) 18 
(5) 14 
(2) 22 
(1) 23* 
(I) 27 
(I) 22 
(I) 2 
(2) 17t 
(2) 12 
(2) 34 
(3) 13t 
(I) 1 
(4) 16 
(4) 1611 
(I41 
(13) 
(19) 
(16) 
(20) 
(30) 
(16) 
(12) 
(15) 
(18) 
(24) 
(14) 
(0) 
(IO) 
(8) 
(14) 
(IO) 
(I) 
(12) 
(12) 
*No re-check of therapy data. tTest for homogeneity within country: 
P < 0.001. *Test for homogeneity within country: P= O.l83(RT), 
P= 0.574(CT). STest for homogeneity within country: P= 0.275. 
IlTest for homogeneity between countries: P < 0.001, between regis- 
tries: P < 0.001. 
Our findings on the proportion of surgical resections for 
colorectal cancers in 1987 can help the interpretation of the 
EUROCARE finding of significant between-country differ- 
ences in colon and rectal cancer survival (cases occurring 
between 1978 and 1985). Within the 15 cancer registry areas 
of this study, the age-adjusted proportion of patients who 
received surgical resection correlated positively with the 5- 
year relative survival probability (Pearson’s r = 0.7, P= 0.02 
for colon and Pearson’s r= 0.6, P= 0.05 for rectum). The 
most likely determinant of this correlation is stage at diagnosis: 
both proportion of resected patients and survival probability 
correlate with this variable. However, quality of, and access to 
surgery, as well as access to endoscopy, may differ among 
countries and registry areas [9], and these may also contribute 
to inter-country survival differences. Unfortunately, the stag- 
ing information routinely available to registries is incomplete 
and insufficiently standardised, and more detailed compari- 
sons are not possible. 
Because cancer regisrries aim to record all the colorecral 
cancer cases in defined areas, the findings of this study are not 
influenced by the socio-demographic factors that often affect 
access to individual hospitals. These population-based results 
therefore probably reflect the real health care situation in the 
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areas considered, although one small caveat would be that 
registries, particularly small ones, may be more likely to be 
present in areas where the local medical community has 
above-average interest in oncology, and this could positively 
influence the standard and availability of care in those areas. 
In conclusion, the proportion of patients undergoing surgi- 
cal resection for colorectal cancers varied widely across Europe 
in 1987. Since this variation correlates positively with the 5 
year survival probability for these cancers (as reported in the 
EUROCARE study [I]), it may be part of the explanation for 
the major differences in survival for these cancers among 
European populations. Factors such as diagnostic procedures 
and their relation to stage, which determine treatment and in 
particular whether a patient is resected, are currently being 
investigated by the EUROCARE group. 
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